{"id":"https://openalex.org/W4249350366","doi":"https://doi.org/10.1158/1535-7163.targ-11-a174","title":"Abstract A174: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and cetuximab.","display_name":"Abstract A174: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and cetuximab.","publication_year":2011,"publication_date":"2011-11-01","ids":{"openalex":"https://openalex.org/W4249350366","doi":"https://doi.org/10.1158/1535-7163.targ-11-a174"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-11-a174","doi":"https://doi.org/10.1158/1535-7163.targ-11-a174","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-11-a174","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111839131","display_name":"Neil N. Senzer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087725","display_name":"Mary Crowley Cancer Research Center","ror":"https://ror.org/002ksg449","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210087725"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neil Senzer","raw_affiliation_strings":["1Mary Crowley Cancer Center, Dallas, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Mary Crowley Cancer Center, Dallas, TX;","institution_ids":["https://openalex.org/I4210087725"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088419169","display_name":"Daniel W. Bowles","orcid":"https://orcid.org/0000-0003-1406-0963","observed_orcids":["https://orcid.org/0000-0003-1406-0963"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Bowles","raw_affiliation_strings":["2University of Colorado Cancer Center, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Colorado Cancer Center, Aurora, CO;","institution_ids":["https://openalex.org/I4210134151"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110382646","display_name":"Roger B. Cohen","orcid":"https://orcid.org/0009-0004-7423-2653","observed_orcids":["https://orcid.org/0009-0004-7423-2653"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roger B. Cohen","raw_affiliation_strings":["3University of Pennsylvania Abramson Cancer Center, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3University of Pennsylvania Abramson Cancer Center, Philadelphia, PA;","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037102866","display_name":"Alex C. H. Vo","orcid":"https://orcid.org/0009-0004-8037-2521","observed_orcids":["https://orcid.org/0009-0004-8037-2521"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex Vo","raw_affiliation_strings":["4Oncothyreon, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Oncothyreon, Inc., Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033878540","display_name":"Kevin M. Klucher","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin Klucher","raw_affiliation_strings":["4Oncothyreon, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Oncothyreon, Inc., Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Scott Peterson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Peterson","raw_affiliation_strings":["4Oncothyreon, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Oncothyreon, Inc., Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029892731","display_name":"Diana Felice Hausman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Diana F. Hausman","raw_affiliation_strings":["4Oncothyreon, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Oncothyreon, Inc., Seattle, WA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5107936741","display_name":"Antonio Jimeno","orcid":"https://orcid.org/0000-0001-8560-0440","observed_orcids":["https://orcid.org/0000-0001-8560-0440"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Antonio Jimeno","raw_affiliation_strings":["2University of Colorado Cancer Center, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Colorado Cancer Center, Aurora, CO;","institution_ids":["https://openalex.org/I4210134151"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"11_Supplement","first_page":"A174","last_page":"A174"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.6693999767303467,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.6693999767303467,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.3118000030517578,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.004600000102072954,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/px-866","display_name":"PX-866","score":0.9860000014305115},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9779999852180481},{"id":"https://openalex.org/keywords/egfr-inhibition","display_name":"EGFR inhibition","score":0.734000027179718},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.9580000042915344},{"id":"https://openalex.org/keywords/head-and-neck-squamous-cell-carcinoma","display_name":"head and neck squamous cell carcinoma","score":0.9509999752044678},{"id":"https://openalex.org/keywords/egfr-inhibitor-resistance","display_name":"EGFR inhibitor resistance","score":0.7429999709129333},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7699999809265137},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.859000027179718},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7820000052452087},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8299999833106995},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.6539999842643738},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6159999966621399}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.980148434638977},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.839144229888916},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6528481245040894},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.581536591053009},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5548396110534668},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5132534503936768},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4894212782382965},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4465555250644684},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.4306764602661133},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3299919664859772},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.23982733488082886},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.18543297052383423}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-11-a174","doi":"https://doi.org/10.1158/1535-7163.targ-11-a174","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-11-a174","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2335069544","https://openalex.org/W2071647145","https://openalex.org/W2146634767","https://openalex.org/W2149584982","https://openalex.org/W2531168802","https://openalex.org/W2245844780","https://openalex.org/W2017200231","https://openalex.org/W2163898107","https://openalex.org/W2055994355","https://openalex.org/W2260300870"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Inhibition":[2],"of":[3,16,26,34,51,59,66,95,112,132,155,185,210,230,307,337,387,416,438,466,477,495,504,514,527,543],"the":[4,8,27,43,133,272,305,345,427,436,471,486,489,501,544],"EGFR":[5,37,76,244,398],"pathway":[6],"by":[7],"monoclonal":[9],"antibody":[10],"cetuximab":[11,117,144,186,256,354,457,484,520,522],"is":[12,39,55,135,138,485,497,532],"an":[13,47,243,397],"important":[14],"component":[15],"treatment":[17,169,241],"for":[18,170,192,364,382,431,506],"colorectal":[19],"cancer":[20],"(CRC)":[21],"and":[22,29,61,72,98,137,152,200,227,248,257,260,271,282,302,327,378,409,440,448,456,530,550],"squamous":[23],"cell":[24],"carcinoma":[25],"head":[28],"neck":[30],"(SCCHN).":[31],"One":[32],"mechanism":[33],"resistance":[35],"to":[36,341,357,422,470,500],"inhibition":[38],"increased":[40],"signaling":[41],"through":[42],"PI-3K":[44],"pathway.":[45],"PX-866,":[46],"irreversible":[48],"pan-isoform":[49],"inhibitor":[50],"Class":[52],"1":[53,81,130,201,261,379,403,410],"PI-3K,":[54],"active":[56],"in":[57,73,114,120,206,312,368,443,464,479,524],"models":[58,65],"CRC":[60,125,199],"direct":[62],"patient":[63],"tumor":[64,444],"SCCHN":[67,204],"as":[68,426,488],"a":[69,79,90,108,161,165,383],"single":[70,83,490,507],"agent":[71,84,491,508],"combination":[74,115,346,480],"with":[75,101,116,123,198,203,218,242,347,424,454,461,481],"inhibitors.":[77],"In":[78,389],"Phase":[80,109,274,474,511],"study,":[82],"PX-866":[85,113,157,211,278,342,349,455,478,518],"was":[86,99,118,172,176,190,371,402,419,458],"well":[87,459],"tolerated":[88,92],"at":[89,149,279],"maximum":[91],"dose":[93,208,276,284,476,483],"(MTD)":[94],"8":[96,215,280],"mg/day":[97,281],"associated":[100],"anti-tumor":[102],"activity.":[103],"Based":[104],"on":[105,160,353],"these":[106,369],"results,":[107],"1/2":[110,311],"study":[111,134,516],"initiated":[119],"patients":[121],"(pts)":[122],"advanced":[124],"or":[126,344],"SCCHN.":[127],"The":[128,287,413,473,493,510],"phase":[129],"portion":[131,513],"complete,":[136],"reported":[139],"here.":[140],"Methods:":[141],"Pts":[142],"received":[143,239,254,265,396,418],"IV":[145],"once":[146,158],"per":[147],"week":[148],"full":[150,283,482],"doses":[151,154],"escalating":[153],"oral":[156],"daily":[159],"21-day":[162],"cycle":[163],"using":[164],"3+3":[166],"design.":[167],"Prophylactic":[168],"rash":[171],"required.":[173],"Tumor":[174],"restaging":[175],"performed":[177],"every":[178],"two":[179,207],"cycles.":[180],"PK":[181,355],"assessments":[182,434],"included":[183,277,293],"evaluation":[184],"levels.":[187],"Archived":[188],"tissue":[189],"collected":[191],"biomarker":[193],"assessment.":[194],"Results:":[195],"10":[196],"pts":[197,237,250,333,361,370,392,528],"pt":[202,262],"enrolled":[205],"cohorts":[209],"(6":[212],"mg":[213,216],"n=4;":[214],"n=7)":[217],"median":[219,228,414],"age":[220],"58":[221],"yrs":[222],"(35\u201382);":[223],"all":[224],"ECOG":[225],"0/1;":[226],"number":[229,415],"prior":[231,240,255],"systemic":[232],"treatments":[233],"4":[234,249,372],"(2\u20138).":[235],"Seven":[236],"had":[238,253,264,334,350,394],"inhibitor,":[245,399],"including":[246],"3":[247,320,324,329,375,406],"each":[251],"who":[252,263,393],"panitumumab,":[258],"respectively,":[259],"both.":[266],"There":[267],"were":[268,309,318,362],"no":[269,351,462],"DLTs,":[270],"recommended":[273],"2":[275,332,475,512,525],"weekly":[285],"cetuximab.":[286,348,509],"most":[288,428],"common":[289,429],"adverse":[290],"events":[291],"(AEs)":[292],"diarrhea,":[294],"hypomagnesemia,":[295],"nausea/vomiting,":[296],"dehydration,":[297],"fatigue,":[298],"rash,":[299],"asthenia,":[300],"constipation":[301],"weight":[303],"loss,":[304],"majority":[306],"which":[308],"Gr":[310,315,319,323,328],"severity.":[313],"Treatment-related":[314],"3/4":[316],"AEs":[317,336],"diarrhea":[321,338],"(n=1),":[322],"hyponatremia":[325],"(n=1)":[326],"hypokalemia":[330],"(n=1).":[331],"serious":[335],"considered":[339],"related":[340],"alone":[343,523],"effect":[352],"compared":[356,499],"historical":[358,502],"data.":[359],"Eight":[360],"evaluable":[363],"response;":[365],"best":[366,400],"response":[367,401],"PR":[373,404],"(50%),":[374],"SD":[376,407],"(38%)":[377],"PD":[380,411,425],"(12%),":[381],"disease":[384],"control":[385],"rate":[386],"88%.":[388],"5":[390],"response-evaluable":[391],"previously":[395],"(20%),":[405],"(60%)":[408],"(20%).":[412],"cycles":[417],"6":[420],"(1":[421],"11),":[423],"reason":[430],"discontinuation.":[432],"Biomarker":[433],"evaluating":[435],"presence":[437],"PIK3CA":[439],"Kras":[441],"mutations":[442],"samples":[445],"are":[446],"ongoing":[447],"will":[449],"be":[450],"presented.":[451],"Conclusions:":[452],"Treatment":[453],"tolerated,":[460],"increase":[463],"toxicity":[465],"either":[467],"drug":[468],"attributable":[469],"combination.":[472],"same":[487],"MTD.":[492],"ORR":[494,503],"50%":[496],"encouraging":[498],"11%":[505],"this":[515],"comparing":[517],"+":[519],"vs.":[521],"groups":[526],"(CRC":[529],"SCCHN)":[531],"now":[533],"enrolling.":[534],"Citation":[535],"Format:":[536],"{Authors}.":[537],"{Abstract":[538],"title}":[539],"[abstract].":[540],"In:":[541],"Proceedings":[542],"AACR-NCI-EORTC":[545],"International":[546],"Conference:":[547],"Molecular":[548],"Targets":[549],"Cancer":[551,563],"Therapeutics;":[552],"2011":[553],"Nov":[554],"12-16;":[555],"San":[556],"Francisco,":[557],"CA.":[558],"Philadelphia":[559],"(PA):":[560],"AACR;":[561],"Mol":[562],"Ther":[564],"2011;10(11":[565],"Suppl):Abstract":[566],"nr":[567],"A174.":[568]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-05-12T00:00:00"}